Amendments to the Claims:

Claims 1-4 (Cancelled)

Claim 5. (Previously amended) A method of inducing apoptosis in a cell in a mammal diagnosed as having a proliferative disease, said method comprising administering to said mammal an a modified antisense nucleic acid oligonucleotide of length sufficient to inhibit an inhibitor of apoptosis (IAP) biological activity, wherein said antisense nucleic acid oligonucleotide is complementary to a portion of human X-linked IAP (XIAP) (SEQ ID NO:3).

Claims 6-8 (Cancelled)

Claim 9. (Previously added) A method of treating a patient diagnosed as having a proliferative disease, said method comprising administering to said patient an a modified antisense nucleic acid oligonucleotide of length sufficient to inhibit an inhibitor of apoptosis (IAP) biological activity, wherein said antisense nucleic acid oligonucleotide is complementary to a portion of human X-linked IAP (XIAP) (SEQ ID NO:3).

Claim 10. (Previously added) The method of claim 9, wherein said mammal is a human.

Claim 11. (Previously added) The method of claim 9, wherein said proliferative disease is cancer.

Claim 12. (Previously added) The method of claim 11, wherein said cancer is ovarian cancer, adenocarcinoma, lymphoma, or pancreatic cancer.

Claim 13. (Previously added) The method of claim 5, wherein said mammal is a human.

Claim 14. (Previously added) The method of claim 5, wherein said proliferative disease is cancer.

Claim 15. (Previously added) The method of claim 14, wherein said cancer is ovarian cancer, adenocarcinoma, lymphoma, or pancreatic cancer.